Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.
Short-Course Radiation May Be Feasible in Older Rectal Cancer Population
A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
Data from a phase 2 study support further development of sacituzumab tirumotecan plus pembrolizumab in metastatic castration-resistant prostate cancer.
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
Vickie Baracos, PhD, discusses recent results that investigate cancer cachexia and how the RNome of the muscle plays a role.
